Metsera, Inc. (MTSR)
$70.50+0.00%Close
BUYBULL · day 25
Key stats
- Market cap
- $7.4B
- Beta
- 1.70
- P/E (TTM)
- -39.83
- 1W
- -15.24%
- 1M
- +33.37%
- vs SPY 1W
- -16.40%
- vs SPY 1M
- +30.38%
Industry peers
FMP comparable companies · ranked by market cap
- PCVXBUYVaxcyte, Inc.$9.4BRECOVERYQ 26$65.02+9.78%
- NUVLBUYNuvalent, Inc.$9.1BBULLQ 42$123.96+0.00%
- AXSMSELLAxsome Therapeutics, Inc.$8.8BCRISISQ 34$170.08-1.02%
- ARWRSELLArrowhead Pharmaceuticals, Inc.$8.6BCRISISQ 12$60.74+3.31%
- CYTKSELLCytokinetics, Incorporated$7.7BCRISISQ 9$62.01+1.45%
- MRUSMerus N.V.$6.8B$90.00
- ACLXArcellx, Inc.$6.7B$115.07
- ABVXSELLAbivax S.A.$6.5BCRISISQ 57$89.05-1.01%
- RYTMSELLRhythm Pharmaceuticals, Inc.$6.1BBEARQ 20$89.64+1.27%
- CRSPSELLCRISPR Therapeutics AG$4.9BBEARQ 20$50.44+5.85%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on MTSR?
- LOPJLB’s latest quantitative signal on Metsera, Inc. (MTSR) is BUY in a BULL regime. Signals are updated daily.
- What market regime is MTSR in?
- Metsera, Inc. (MTSR) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Metsera, Inc. (MTSR) do?
- Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overwe…